Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: Effects of a single dose methotrexate

Rheumatology

Volumn 33, Issue 11, 1994, Pages 1017-1024

  Barrera, P ^a   Boerbooms, A M Th ^a   Demacker, P N M ^b   Van De Putte, L B A ^a   Gallati, H ^c   Van Der Meer, J W M ^b  

^a University Hospital Higmegen ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cytokines; Methotrexate; Rheumatoid arthritis; Soluble TNF receptors

Indexed keywords

CYTOKINE; FOLIC ACID ANTAGONIST; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CYTOKINES; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MONOCYTES; OSMOLAR CONCENTRATION; RECEPTORS, CYTOKINE; SOLUBILITY; TIME FACTORS;

EID: 0028604305     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/33.11.1017     Document Type: Article

References (45)

1. Williams HJ, Willkens RF, Samuelson CO et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1985;28:721–30.
2. Weinblatt ME, Kaplan H, Germain BF et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. Arthritis Rheum 1990;33:330–8.
3. Chabner BA, Allegra CJ, Curt GA et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985;76:907–12.
4. Bleyer WA. The clinical pharmacology of methotrexate: new application of an old drug. Cancer 1978;41:36–51.
5. Furst DE, Kremmer JM. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1988;31:305–14.
6. Cronstein BN. Molecular mechanism of methotrexate action in inflammation. Inflammation 1992;16:150–62.
7. 2) receptor. Rev Esp Rheumatol 1993;20 (suppl):6.
8. Wolf R, Asako H, Granger DN. Adenosine mediates methotrexate-induced attenuation of leukocyte adherence and emigration in postcapillary venules. Arthritis Rheum 1992;35:S35.
9. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low dose methotrexate. Arthritis Rheum 1989;32:1065–73.
10. Meyer FA, Yaron I, Mashiah V, Yaron M. Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts. J Rheumatol 1993;20:238–42.
11. O’Callaghan JW, Forrest MJ, Brooks PM. Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients. Rheumatol Int 1988;8:41–5.
12. Laurindo IMM, Mello SBV, de Falco V, Yoshinari N, Cossermelli W. Action of methotrexate on superoxide production (abstract). Rev Esp Rheumatol 1993;20 (suppl. 1):6 (12).
13. 4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum 1990;33:1149–55.
14. Leroux JL, Damon M, Chavis C, Crastes de Paulet A, Blotman F. Effects du méthotrexate sur la synthèse de leucotriènes et de dérivés de la lipoxygénase par les poynucléaires au cours de la polyarthrite rhumatoide. Rev Rhum Mai Ostéo 1992;59:87–91.
15. Segal R, Yaron M, Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990;3:190–9.
16. Miller LC, Cohen EE, Orencole SF, Schaller JG, Savage N, Dinarello CA. Interleukin-1β is structurally related to dihydrifolate reductase: effects of methotrexate on IL-1 (abstract). Cytokine Res 1988;7:1.49.
17. Segal R, Mozes E, Yaron M, Tartakowsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989;32:370–7.
18. Segal R, Yaron M, Tartakowsky B. Rescue of interleukin-1 activity by leucovorin following inhibition by methotrexate in a murine in vitro system. Arthritis Rheum 1990;33:1745–9.
19. Ridge SC, Rath N, Gallivan J, Zabriske J, Oronsky AL, Kerwar SS. Studies in the effect of D-penicillamine, gold thioglucose and methotrexate on streptococcal cell wall arthritis J Rheumatol 1986;13:895–8.
20. Johnson WJ, DiMartino MJ, Meunier PC, Muirhead KA, Hanna N. Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis. J Rheumatol 1988;15:745–9.
21. Chang DM, Weinblatt ME, Schur PH. The effects of methotrexate on interleukin-1 in patients with rheumatoid arthritis. J Rheumatol 1992;19:1678–82.
22. Thomas R, Carroll GJ. Reduction of leukocyte and interleukin-1β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993;36:1244–52.
23. Couret M, Combe B, Reme J, Sany J. Production d’interleukine 2 et d’interferon gamma dans la polyarthrite rhumatoïde au cours d’une étude longitudinale chez des patients traités par méthotrexate. Rev Rhum 1990;57:641–5.
24. Aaron SL. Augmentation of IL-2 secretion by methotrexate therapy of rheumatoid arthritis (abstract). Arthritis Rheum 1989;32:S60.
25. Barrera P, Boerbooms AMth, Janssen EM et al. Circulating soluble TNF receptors and interleukin-2 receptors, tumour necrosis factor alpha and interleukin-6 in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993;36:1070–9.
26. Segal R, Caspi D, Tisher M, Vigler I, Yaron M. Short term effects of low dose methotrexate on the acute phase reaction in rheumatoid arthritis patients. J Rheumatol 1989;16:914–8.
27. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
28. Van Deuren M, van der Ven-Jongekrijg J, Keuter M, Demacker PNM, van der Meer JWM. Cytokine production in whole-blood cultures. J Int Fed Clin Chem 1993;5:216–21.
29. Lonnemann G, Endres S, Van der Meer JWM, Cannon JG, Dinarello CA. Differences in the synthesis and kinetics of release of interleukin-1α, interleukin-1β and tumour necrosis factor from human mononuclear cells. Eur J Immunol 1989;19:1531–6.
30. Lonnemann G, Endres S, Van der Meer JWM, Cannon JG, Dinarello CA. A radioimmunoassay for human interleukin-1α: measurement of IL-1α produced in vitro by human blood mononuclear cells stimulated with endotoxin. Lymphokine Res 1988;7:75–84.
31. Cannon JG, Van der Meer JWM, Kwiatkowski D et al. Interleukin-1β in human plasma: Optimization of blood collection, plasma extraction and radioimmunoassay methods. Lymphokine Res 1988;7: 457–67.
32. Endres S, Ghorbani R, Lonnemann G, Van der Meer JWM, Dinarello CA. Measurement of immunoreactive interleukin-1β from human mononuclear cells: Optimization of recovery, intrasubject consistency, and comparison with interleukin-1α and tumour necrosis factor. Clin Immunol Immunopathol 1988;49: 424–38.
33. Van der Meer JWM, Endres S, Lonnemann G et al. Concentrations of immunoreactive human tumour necrosis factor alpha produced by human mononuclear cells in vitro. J Leukocyte Biol 1988;43:216–23.
34. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA. Production of interleukin-1 receptor antagonist and interleukin-1β by peripheral blood mononuclear cells is differentially regulated. Blood 1991;78:1275–81.
35. Helle M, Boeije L, Aarden LA. Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol 1988;18:1535–40.
36. Porteu F, Nathan C. Shedding of tumour necrosis factor receptors by activated human neutrophils J Exp Med 1990;172:599–607.
37. Cope AP, Aderka D, Doherty M et al. Increased levels of soluble tumour necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases Arthritis Rheum 1992;35:1160–9.
38. Chu CO, Deleuran BW, Field M, et al. Increased expression of TNF receptors in the synovial tissue of rheumatoid arthritis Arthritis Rheum 1992;35;S174.
39. Taylor DJ. Cytokine combinations increase p75 rumour necrosis factor receptor binding and stimulate receptor shedding in rheumatoid synovial fibroblasts Arthritis Rheum 1994;37:232–5.
40. Maini RN, Brennan FM, Williams R et al. TNF-α in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol 1993;11:S173–5.
41. Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor α. Arthritis Rheum 1993;36:1681–90.
42. Van Deuren M, van der Ven-Jongekrijg J, Demacker PNM et al. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections J Infect Dis 1994;169:157–61.
43. Nerad JL, Griffiths JK, Van der Meer JWM et al. Interleukin-1β, IL-1 receptor antagonist and TNFα production in whole blood. J Leukocyte Biol 1992;52:687–92.
44. Zangerle PF, De Groote D, Lopez M et al. Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IL-2, IFN-τ and GM-CSF) in whole blood: II. Application of rheumatoid arthritis and osteoarthritis Cytokine 1992;4368–75.
45. Lebsack ME, Paul CC, Martindale JJ, Catalano MA. A dose and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis Arthritis Rheum 1993;36:S9.